Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed diagnosis of 1 of the following:
• •* Intrahepatic cholangiocarcinoma
• •* Metastatic cancer confined to the liver
• •Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral CT scan
• •Must have tumor volume ≤ 50% of total liver volume based on visual estimation
• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-2
• •ANC ≥ 1,500/mm\^3
• •Platelet count ≥ 75,000/mm\^3
• •Serum creatinine ≤ 2.0 mg/dL
• •Serum bilirubin ≤ 1.5 times upper limit of normal
• •Albumin ≥ 2.0 g/dL
• •No baseline symptoms or laboratory values \> grade 2 in severity by NCI CTCAE v 3.0 criteria
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •No malabsorption syndrome
• •No severe liver dysfunction or pulmonary insufficiency
• •No complete occlusion of the main portal vein
• •No contraindication to iodine-based contrast agents
• •No contraindication to hepatic artery catheterization (e.g., vascular abnormalities or bleeding diathesis)
• •No prior unanticipated severe reaction to fluoropyrimidine therapy, known hypersensitivity to fluorouracil, or known dihydropyrimidine dehydrogenase deficiency
• •PRIOR CONCURRENT THERAPY:
• •No prior radiotherapy to the liver
• •No more than 2 prior therapies for metastatic disease to the liver
• •No prior intervention to or compromise of the Ampulla of Vater
• •At least 4 weeks since prior and no concurrent sorivudine or brivudine
• •No concurrent cimetidine